BioAmber (NYSE: BIOA) reported Q1 EPS of ($0.25), $0.02 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $2.5 million versus the consensus estimate of $2.37 million.

For earnings history and earnings-related data on BioAmber (BIOA) click here.